Reported September 20, 2026: 'Australia's Telix Pharma Agrees To Buy Germany's ITM Isotope For About $1.65B'

Telix Pharma, an Australian biotechnology company, has agreed to acquire Germany's ITM Isotope for approximately $1.65 billion. This strategic move aims to enhance Telix's position in the radiopharmaceutical market. The acquisition is expected to bolster Telix's product offerings and expand its operational capabilities.